Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorGregory Hinkle
Life of this patent
Estimating the term…
Abstract
The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
Claims31
A single-stranded antisense polynucleotide agent for inhibiting expression of a Programmed cell death 1 ligand 1 (PD-L1) gene, wherein the agent comprises 4 to 50 contiguous nucleotides, wherein at least one of the contiguous nucleotides is a modified nucleotide, and wherein the nucleotide sequence of the agent is 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs:1-5.
-6. (canceled)
-16. (canceled)
-21. (canceled)
(canceled)
-43. (canceled)
-53. (canceled)
(canceled)
(canceled)
-60. (canceled)
-75. (canceled)
Dependencies are inferred from the claim text.